These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 35103907)

  • 1. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    Haque W; Teh C; Butler EB; Teh BS
    J Neurooncol; 2022 Mar; 157(1):137-146. PubMed ID: 35103907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
    Kinslow CJ; Rae AI; Taparra K; Kumar P; Siegelin MD; Grinband J; Gill BJA; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Horowitz DP; Kachnic LA; Neugut AI; Yu JB; Cheng SK; Wang TJC
    Clin Cancer Res; 2023 Nov; 29(21):4399-4407. PubMed ID: 37611077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
    JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow CJ; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
    J Neurooncol; 2024 Jan; 166(1):73-78. PubMed ID: 38114801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
    Buyuktepe M; Kaplan I; Bayatli E; Dogan H; Ugur HC
    J Neurooncol; 2023 Aug; 164(1):171-177. PubMed ID: 37474746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM].
    Gibson D; Vo AH; Lambing H; Bhattacharya P; Tahir P; Chehab FF; Butowski N
    BMC Neurol; 2024 Mar; 24(1):103. PubMed ID: 38521933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
    Petrova EI; Galstyan SA; Telysheva EN; Ryzhova MV
    Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):52-58. PubMed ID: 38054227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.
    Fleming JL; Pugh SL; Fisher BJ; Lesser GJ; Macdonald DR; Bell EH; McElroy JP; Becker AP; Timmers CD; Aldape KD; Rogers CL; Doyle TJ; Werner-Wasik M; Bahary JP; Yu HM; D'Souza DP; Laack NN; Sneed PK; Kwok Y; Won M; Mehta MP; Chakravarti A
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34589661
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
    Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
    Sasaki T; Fukai J; Kodama Y; Hirose T; Okita Y; Moriuchi S; Nonaka M; Tsuyuguchi N; Terakawa Y; Uda T; Tomogane Y; Kinoshita M; Nishida N; Izumoto S; Nakajima Y; Arita H; Ishibashi K; Shofuda T; Kanematsu D; Yoshioka E; Mano M; Fujita K; Uematsu Y; Nakao N; Mori K; Kanemura Y
    J Neurooncol; 2018 Nov; 140(2):329-339. PubMed ID: 30076584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas.
    Zhao B; Qi H; Ma W
    JAMA Oncol; 2023 Dec; 9(12):1734-1735. PubMed ID: 37856142
    [No Abstract]   [Full Text] [Related]  

  • 12. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas-Reply.
    Kinslow CJ; Cheng SK; Wang TJC
    JAMA Oncol; 2023 Dec; 9(12):1735-1736. PubMed ID: 37856114
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
    Rosas-Alonso R; Colmenarejo-Fernández J; Pernía O; Burdiel M; Rodríguez-Antolín C; Losantos-García I; Rubio T; Moreno-Velasco R; Esteban-Rodríguez I; Martínez-Marín V; Yubero P; Costa-Fraga N; Díaz-Lagares A; López-López R; Díaz-Martin E; García JF; Sánchez CV; Gandía-González ML; Moreno-Bueno G; de Castro J; de Cáceres II
    Sci Rep; 2024 May; 14(1):11398. PubMed ID: 38762534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas.
    Smrdel U; Škufca Smrdel AC; Podlesek A; Skoblar Vidmar M; Kos G; Markovic J; Jereb J; Knific J; Rus T
    Croat Med J; 2023 Dec; 64(6):383-390. PubMed ID: 38168519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.
    Cheng W; Li M; Cai J; Wang K; Zhang C; Bao Z; Liu Y; Wu A
    J Neurooncol; 2015 Apr; 122(2):303-12. PubMed ID: 25557107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow C; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
    Res Sq; 2023 Oct; ():. PubMed ID: 37886555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.
    Zhang J; Qiu X; Feng J; Liu Y
    Chin Neurosurg J; 2024 Jul; 10(1):24. PubMed ID: 39049072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy.
    Wang PG; Li YT; Pan Y; Gao ZZ; Guan XW; Jia L; Liu FT
    J Neurooncol; 2019 Jan; 141(1):71-81. PubMed ID: 30446901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytic approaches to clinical validation of results from preclinical models of glioblastoma: A systematic review.
    Fitt B; Loy G; Christopher E; Brennan PM; Poon MTC
    PLoS One; 2022; 17(3):e0264740. PubMed ID: 35231064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution.
    Barzegar Behrooz A; Darzi Ramandi H; Latifi-Navid H; Peymani P; Tarharoudi R; Momeni N; Sabaghpour Azarian MM; Eltonsy S; Pour-Rashidi A; Ghavami S
    Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.